Research has indicated that MTE could restore erlotinib and gefitinib efficacy in the resistant NSCLC cell line HCC827/ER, with Axl and c-Met activation in vitro and in vivo, through suppression of EGFR downstream molecules (17). This evidence concerns the gene MET and non-small cell lung carcinoma.